It first appeared in the minutes for the February 22 2024 meeting:
a medicine used in combination with platinum-based chemotherapy indicated for the first-line treatment of adults with metastatic non-small-cell lung cancer caused by changes in a gene called ‘EGFR’ (Epidermal Growth Factor receptor).
In this case, there were 7 months in between the first meeting and the second, rather than the 6 which is more common.